Equities research analysts expect Teligent Inc (NASDAQ:TLGT) to report sales of $13.54 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Teligent’s earnings. The lowest sales estimate is $13.18 million and the highest is $13.75 million. Teligent posted sales of $17.94 million during the same quarter last year, which suggests a negative year over year growth rate of 24.5%. The company is expected to issue its next quarterly earnings report on Tuesday, March 6th.
On average, analysts expect that Teligent will report full-year sales of $13.54 million for the current year, with estimates ranging from $65.14 million to $65.70 million. For the next financial year, analysts anticipate that the firm will post sales of $84.79 million per share, with estimates ranging from $77.31 million to $92.40 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Teligent.
Teligent (NASDAQ:TLGT) last announced its earnings results on Monday, November 6th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.07). The business had revenue of $13.65 million during the quarter, compared to analyst estimates of $19.12 million. Teligent had a negative return on equity of 6.51% and a negative net margin of 16.95%. The firm’s revenue was down 15.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.01 earnings per share.
Several institutional investors and hedge funds have recently made changes to their positions in TLGT. Swiss National Bank boosted its holdings in shares of Teligent by 14.5% in the 2nd quarter. Swiss National Bank now owns 74,800 shares of the company’s stock worth $684,000 after acquiring an additional 9,500 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Teligent by 99.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 59,773 shares of the company’s stock worth $547,000 after buying an additional 29,816 shares in the last quarter. Alliancebernstein L.P. lifted its holdings in Teligent by 19.2% during the 2nd quarter. Alliancebernstein L.P. now owns 37,200 shares of the company’s stock worth $340,000 after buying an additional 6,000 shares in the last quarter. Teachers Advisors LLC lifted its holdings in Teligent by 7.6% during the 2nd quarter. Teachers Advisors LLC now owns 74,109 shares of the company’s stock worth $678,000 after buying an additional 5,216 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its holdings in Teligent by 5.4% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 111,506 shares of the company’s stock worth $1,020,000 after buying an additional 5,691 shares in the last quarter. 72.11% of the stock is currently owned by institutional investors and hedge funds.
Teligent (NASDAQ:TLGT) opened at $3.00 on Friday. The company has a market capitalization of $161.27, a P/E ratio of -13.04, a PEG ratio of 60.40 and a beta of 1.07. The company has a quick ratio of 2.71, a current ratio of 3.28 and a debt-to-equity ratio of 2.23. Teligent has a 1-year low of $2.75 and a 1-year high of $9.54.
COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Expect Teligent Inc (TLGT) Will Announce Quarterly Sales of $13.54 Million” was posted by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/09/zacks-analysts-expect-teligent-inc-tlgt-will-announce-quarterly-sales-of-13-54-million.html.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.